Welcome to Scribd, the world's digital library. Read, publish, and share books and documents. See more
Download
Standard view
Full view
of .
Look up keyword
Like this
1Activity
0 of .
Results for:
No results containing your search query
P. 1
Novartis Pharmaceuticals v. Lupin et. al.

Novartis Pharmaceuticals v. Lupin et. al.

Ratings: (0)|Views: 202|Likes:
Published by PriorSmart
Official Complaint for Patent Infringement in Civil Action No. 2:12-cv-04552-WJM-MF: Novartis Pharmaceuticals Corporation v. Lupin Ltd. et. al. Filed in U.S. District Court for the District of New Jersey, the Hon. William J. Martini presiding. See http://news.priorsmart.com/-l6rL for more info.
Official Complaint for Patent Infringement in Civil Action No. 2:12-cv-04552-WJM-MF: Novartis Pharmaceuticals Corporation v. Lupin Ltd. et. al. Filed in U.S. District Court for the District of New Jersey, the Hon. William J. Martini presiding. See http://news.priorsmart.com/-l6rL for more info.

More info:

Published by: PriorSmart on Jul 24, 2012
Copyright:Public Domain

Availability:

Read on Scribd mobile: iPhone, iPad and Android.
download as PDF, TXT or read online from Scribd
See more
See less

02/01/2013

pdf

text

original

 
 William J. O’ShaughnessyMCCARTER & ENGLISH LLPFour Gateway Center100 Mulberry StreetNewark, NJ 07102Tel: (973) 639-2094woshaughnessy@mccarter.com
 Attorneys for Novartis PharmaceuticalsCorporation
 OF COUNSEL:Scott FamilantJennifer GordonBAKER BOTTS LLP30 Rockefeller PlazaNew York, NY 10112-4498Tel: (212) 408-2500scott.familant@bakerbotts.com jennifer.gordon@bakerbotts.com 
 Attorneys for Novartis PharmaceuticalsCorporation
 
IN THE UNITED STATES DISTRICT COURTFOR THE DISTRICT OF NEW JERSEY
NOVARTIS PHARMACEUTICALSCORPORATIONPlaintiff,v.LUPIN LTD. and LUPINPHARMACEUTICALS, INC.,Defendants.)))))))))))))Civil Action No. _____
COMPLAINT
Plaintiff Novartis Pharmaceuticals Corporation (“Novartis”), by its undersignedattorneys, brings this action against Defendants Lupin Ltd. and Lupin Pharmaceuticals, Inc.(“Lupin Inc.”; collectively “Lupin”), and hereby alleges as follows:
Nature of the Action
 1.
 
This is an action for infringement of United States Patent No. 6,294,197 (the“’197 patent”) under the Patent Laws of the United States, 35 U.S.C. §100
et seq.
, particularly§271(e)(2).
Case 2:33-av-00001 Document 15533 Filed 07/20/12 Page 1 of 12 PageID: 320510
 
2.
 
This action relates to Defendants’ filing Abbreviated New Drug Application(“ANDA”) No. 78-946 with the United States Food and Drug Administration (“FDA”), seekingapproval to commercially market generic versions of Novartis’s D
IOVAN
H
CT
®
drug product inthe United States, including New Jersey.
The Parties
 3.
 
Plaintiff Novartis is a corporation organized and existing under the laws of Delaware, with a principal place of business at One Hanover Health Plaza, East Hanover, NewJersey 07936.4.
 
On information and belief, Lupin Ltd. is a company organized and existing underthe laws of India, having a principal place of business at B/4 Laxami Towers, Branda KurlaComplex, Bandra (East), Mumbai, Maharashtra 400 051, India.5.
 
On information and belief, Lupin Inc. is a corporation organized and existingunder the laws of Virginia, having a principal place of business at Harbor Place Tower, 111South Calvert Street, 21st floor, Baltimore, Maryland 21202.6.
 
On information and belief, Lupin Ltd. and Lupin Inc., acting in their ownindividual capacities and/or in privity and/or concert with one another, are in the business of making and selling pharmaceutical products in the United States, including New Jersey.
Subject Matter Jurisdiction and Venue
7.
 
This Court has jurisdiction over the subject matter of this action pursuant to 28U.S.C. §§ 1331 and 1338.
Case 2:33-av-00001 Document 15533 Filed 07/20/12 Page 2 of 12 PageID: 320511
 
8.
 
Venue is proper in the judicial district pursuant to 28 U.S.C. §§ 1391(b, c) and/or1400(b).
Personal Jurisdiction
9.
 
On information and belief, Lupin Ltd. and Lupin Inc. operate as an integrated,unitary business. For example, in its 2011 Annual Report, Lupin Ltd. identifies Lupin Inc. as awholly-owned subsidiary and ascribes this subsidiary’s activities to “the Company,”
i.e.
, LupinLtd.10.
 
The Annual 2011 Report also provides consolidated financial information,treating Lupin Ltd. and its various subsidiaries (including Lupin Inc.) and associates as a“Group,” and reports that annual revenues in the US for 2011 exceeded $400 million dollars.11.
 
Lupin Ltd. maintains a web-site at the uniform resource locator (URL)http://www.lupinworld.com. The web-site’s “/businesssegment.htm” page reflects that thecompany divides its “formulation business” into seven regional markets, including the “USA”and identifies Lupin Inc. as the entity responsible for the U.S. market. The“/contact.htm#formulation” page of the web-site further indicates that Lupin Inc. is Lupin Ltd.’s“American” contact within the company’s “Global Pharmaceutical Business.”12.
 
Lupin Inc. also maintains a web-site at the uniform resource locator (URL)http://www.lupinpharmaceuticals.com. According to that web-site’s “/mission.htm” page, thecompany’s mission and vision is to “capitalize on the strengths of [its] parent company, LupinLimited,” and be positioned “for growth in the US market.”13.
 
On information and belief, Lupin Ltd. and Lupin Inc., acting in their ownindividual capacities and/or in privity and/or concert with one another, developed generic copies
Case 2:33-av-00001 Document 15533 Filed 07/20/12 Page 3 of 12 PageID: 320512

You're Reading a Free Preview

Download
scribd
/*********** DO NOT ALTER ANYTHING BELOW THIS LINE ! ************/ var s_code=s.t();if(s_code)document.write(s_code)//-->